These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 18091589)

  • 1. Valsartan therapy in heart failure after myocardial infarction: the role of endothelial dependent vasorelaxation.
    Thai H; Guarraia D; Johnson N; Goldman S; Gaballa MA
    J Cardiovasc Pharmacol; 2007 Dec; 50(6):703-7. PubMed ID: 18091589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin subtype 1 rReceptor (AT1) blockade improves vasorelaxation in heart failure by up-regulation of endothelial nitric-oxide synthase via activation of the AT2 receptor.
    Thai H; Wollmuth J; Goldman S; Gaballa M
    J Pharmacol Exp Ther; 2003 Dec; 307(3):1171-8. PubMed ID: 14560036
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post-myocardial infarction remodeling.
    Oishi Y; Ozono R; Yoshizumi M; Akishita M; Horiuchi M; Oshima T
    Life Sci; 2006 Dec; 80(1):82-8. PubMed ID: 17023005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement in left ventricular remodeling by the endothelial nitric oxide synthase enhancer AVE9488 after experimental myocardial infarction.
    Fraccarollo D; Widder JD; Galuppo P; Thum T; Tsikas D; Hoffmann M; Ruetten H; Ertl G; Bauersachs J
    Circulation; 2008 Aug; 118(8):818-27. PubMed ID: 18678774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone antagonism improves endothelial-dependent vasorelaxation in heart failure via upregulation of endothelial nitric oxide synthase production.
    Thai HM; Do BQ; Tran TD; Gaballa MA; Goldman S
    J Card Fail; 2006 Apr; 12(3):240-5. PubMed ID: 16624690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 4th communication: improvement of heart failure of rats with myocardial infarction by valasartan.
    Hayashi N; Fujimura Y; Yamamoto S; Kometani M; Nakao K
    Arzneimittelforschung; 1997 May; 47(5):625-9. PubMed ID: 9205776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel mechanism and role of angiotensin II induced vascular endothelial injury in hypertensive diastolic heart failure.
    Yamamoto E; Kataoka K; Shintaku H; Yamashita T; Tokutomi Y; Dong YF; Matsuba S; Ichijo H; Ogawa H; Kim-Mitsuyama S
    Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2569-75. PubMed ID: 17932313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment with angiotensin receptor blockade prevents left ventricular dysfunction and blunts left ventricular remodeling associated with acute myocardial infarction.
    Thai H; Castellano L; Juneman E; Phan H; Do R; Gaballa MA; Goldman S
    Circulation; 2006 Oct; 114(18):1933-9. PubMed ID: 17060375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [On angiotensin II receptor distribution after myocardial infarction in dogs].
    Qu XF; Li JJ; Xi Y; Shen JX; Xiu CH; Yue L; Wang GZ; Huang YL
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Apr; 37(4):358-62. PubMed ID: 19791474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined effects of ramipril and angiotensin II receptor blocker TCV116 on rat congestive heart failure after myocardial infarction.
    Tao ZW; Huang YW; Xia Q; Xu QW
    Chin Med J (Engl); 2005 Jan; 118(2):146-54. PubMed ID: 15667801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.
    Burchill LJ; Velkoska E; Dean RG; Griggs K; Patel SK; Burrell LM
    Clin Sci (Lond); 2012 Dec; 123(11):649-58. PubMed ID: 22715807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effects of valsartan on myocardial calcium/calmodulin-dependent protein kinase-II expression and activity in a rabbit model of heart failure].
    Qu FZ; Liu ZH; Jiang B; Zou C; Li HX; Han LH; Jiang WP
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Jun; 37(6):501-4. PubMed ID: 19927629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction.
    Smith RS; Agata J; Xia CF; Chao L; Chao J
    Life Sci; 2005 Apr; 76(21):2457-71. PubMed ID: 15763077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in ventricular size and function in patients treated with valsartan, captopril, or both after myocardial infarction.
    Solomon SD; Skali H; Anavekar NS; Bourgoun M; Barvik S; Ghali JK; Warnica JW; Khrakovskaya M; Arnold JM; Schwartz Y; Velazquez EJ; Califf RM; McMurray JV; Pfeffer MA
    Circulation; 2005 Jun; 111(25):3411-9. PubMed ID: 15967846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of baseline and changes in systolic blood pressure over time on the effectiveness of valsartan in the Valsartan Heart Failure Trial.
    Anand IS; Rector TS; Kuskowski M; Thomas S; Holwerda NJ; Cohn JN
    Circ Heart Fail; 2008 May; 1(1):34-42. PubMed ID: 19808268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice.
    Higashikuni Y; Takaoka M; Iwata H; Tanaka K; Hirata Y; Nagai R; Sata M
    Hypertens Res; 2012 Jan; 35(1):62-9. PubMed ID: 21833001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Alterations in aortic vasomotor function in rats with chronic heart failure and its mechanism].
    Zhang HL; Zhao M; He X; Jiang HK; Yu XJ; Ma X; Zang WJ
    Sheng Li Xue Bao; 2010 Aug; 62(4):317-24. PubMed ID: 20717632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interventional effect of valsartan on expression of inducible cAMP early repressor and phosphodiesterase 3A in rats after myocardial infarction.
    Ma D; Fu L; Shen J; Zhou P; Gao Y; Xie R; Li Y; Han Y; Wang Y; Wang F
    Eur J Pharmacol; 2009 Jan; 602(2-3):348-54. PubMed ID: 19027736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic infusion of bradykinin delays the progression of heart failure and preserves vascular endothelium-mediated vasodilation in conscious dogs.
    Tonduangu D; Hittinger L; Ghaleh B; Le Corvoisier P; Sambin L; Champagne S; Badoual T; Vincent F; Berdeaux A; Crozatier B; Su JB
    Circulation; 2004 Jan; 109(1):114-9. PubMed ID: 14662711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of endothelium nitric oxide synthase reverses the diminished vasorelaxation in the hindlimb vasculature in ischemic heart failure in vivo.
    Gaballa MA; Goldman S
    J Mol Cell Cardiol; 1999 Jun; 31(6):1243-52. PubMed ID: 10371698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.